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AJH 2004; 17:245–251Background: Circadian blood pressure (BP) measure-
ments provide more information on hypertensive compli-
cations than office BP measurements. The purpose of this
study was to analyze the efficacy of the first-line combi-
nation of perindopril 2 mg plus indapamide 0.625 mg
versus atenolol 50 mg on BP parameters and variability
over 24 h in patients with hypertension.
Methods: A double-blind, randomized, controlled, 12-
month study comparing perindopril/indapamide and
atenolol was performed in 201 patients (age 55.0 years)
with uncomplicated sustained essential hypertension. Am-
bulatory BP measurements (ABPM) were done every 15
min over 24 h.
Results: After 1 year of treatment, the decrease in
systolic BP was significantly greater for perindopril/inda-
pamide than for atenolol during the entire 24-h period
(-13.8 v 9.2 mm Hg), the daytime and the nighttime
periods (P  .01). Diastolic blood pressure (DBP) varia-
tions were comparable for the two groups (7.2 v 8.3
mm Hg, NS). Pulse pressure (PP) reduction was also
Mu¨nster, Mu¨nster, Germany; Hospital Germans Trias y Pujol (RR),
© 2004 by the American Journal of Hypertension, Ltd.
Published by Elsevier Inc.significantly greater for perindopril/indapamide than for
atenolol (for the whole 24 h, 6.6 v 0.9 mm Hg, P 
.001). The through to peak (T/P) BP ratio and the smooth-
ness index were comparable in the two groups for DBP.
For systolic blood pressure (SBP), higher values of the T/P
ratio (0.80 v 0.59) and the smoothness index (1.45 v 0.98;
P  .02) were achieved for the perindopril/indapamide
combination than for atenolol.
Conclusions: The perindopril/indapamide first-line
combination decreased SBP and PP more effectively than
atenolol. Moreover, the BP control effect was smooth and
consistent throughout the 24-h dosing interval and BP
reduction variability was lower than the one induced by
atenolol. Am J Hypertens 2004;17:245–251 © 2004
American Journal of Hypertension, Ltd.
Key Words: Antihypertensive drug treatment, ambu-
latory blood pressure measurement, blood pressure vari-
ability, smoothness index, trough/peak ratio, perindopril/
indapamide combination.H ypertensive subjects are at increased risk formyocardial infarction, heart failure, stroke, pe-ripheral arterial disease, and renal impairment.
Blood pressure (BP) fluctuates constantly over time. This
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utes to end-organ damage. Similar observations have been
made in animal models of hypertension, particularly in
strains of spontaneously hypertensive rats.2
The relationship between BP variability and the alter-
ations of end-organ damage has been studied in hyperten-
sive patients by Parati et al3 and Frattola et al.4 Several
investigations have provided consistent evidence of the
prognostic value of ambulatory BP monitoring (ABPM)
for cardiovascular risk5–9 and have shown that ABPM is
superior to office BP in predicting cardiovascular out-
come.5,7,8 Moreover, nighttime systolic BP (SBP) has
been shown to be a better predictor of cardiovascular
events than the average daytime BP.10
Another goal for innovative antihypertensive drug
treatment is not only to reduce BP but also to “smooth” the
pressure profile over 24 h and to attenuate BP fluctuations,
particularly those related to SBP.11 Although office BP
measurement has been used traditionally for the evaluation
of antihypertensive drugs, ABPM has the advantage of
providing sensitive and reliable BP evaluations over 24 h.
The combinaton of perindopril 2 mg and indapamide
0.625 mg, which contains one half the dose the angioten-
sin-converting enzyme (ACE) inhibitor perindopril and
one quarter the dose of the diuretic indapamide used for
usual treatment, has been shown to be effective as first-line
treatment of hypertension and to have a superior antihy-
pertensive efficacy in comparison with atenolol, enalapril,
losartan, and irbesartan.12–19 When compared with ateno-
lol in hypertensive subjects, the perindopril/indapamide
combination effected a greater reduction in SBP for the
same reduction of diastolic BP (DBP) at both the brachial
and central (thoracic aorta) arterial levels.18,19
The aim of the present study was to determine whether
the first-line combination perindopril/indapamide would
be able to control BP, and mainly SBP, over 24 h and to
buffer the BP variability assessed by ABPM, in compari-
son with the -blocker atenolol used as reference.
Methods
Study Population
The ABPM investigation was an ancillary study of the
PREterax in regression of Arterial Stiffness in a contrOlled
double-bliNd study (REASON). REASON is a multi-
center, controlled, randomized, double-blind, two parallel
group study conducted in 13 countries.18,19 ABPM was
carried out only in the centers able to perform this exam-
ination (32 of 52). Among the 471 hypertensive patients
randomized in REASON, 269 underwent 24-h ABPM. Of
the patients, 68 were excluded from the final analysis
because of a lack of valid ABPM data before or after 1
year of treatment, as described later here. Finally, 201
patients were analyzed in the ABPM study (perindopril/
indapamide group, 107 patients; atenolol group, 94 pa-
tients). These 201 patients were from nine countries
(France, n 52; Australia, n 50; Spain, n 38; Ireland,n  22; Germany, n  16; Switzerland, n  7; Belgium,
n  6; Austria, n  5; The Netherlands, n  5).
The inclusion criteria were uncomplicated essential ar-
terial hypertension (160  SBP 210 mm Hg or 95 
DBP 110 mm Hg) measured in the supine position with
a mercury sphygmomanometer without intake of any an-
tidiabetic, cardiovascular, or cholesterol-lowering drugs.
Informed written consent was obtained from each patient.
The protocol was approved by the Ethics Committees
according to national regulations. The study was con-
ducted in accordance with the Declaration of Helsinki.
Treatments
After a 4-week placebo washout period, the patients were
randomly assigned to receive either perindopril 2 mg plus
indapamide 0.625 mg, or atenolol 50 mg for 1 year. The
medication was taken orally each morning. After 3, 6, or
9 months of treatment, the dose could be adjusted accord-
ing to the conventional BP. In the event of SBP 160 mm
Hg or DBP 90 mm Hg, the dose was increased to two
tablets each morning. Other antihypertensive drugs were
not allowed during the study follow-up.
ABPM
We performed ABPM with equipment validated as class A
or B by the protocols of the British Hypertension Society
or of the Association for the Advancement of Medical
Instrumentation.20,21
A cuff size suitable for the patient’s arm circumference
was selected. The ABPM device was set up during a
normal activity day, just before the drug intake (from 8 to
10 AM), at the end of the washout period and after one year
of treatment. At the second set-up, the same device was
used for a given patient and was installed by the same
investigator on the same arm; the difference between the
first set-up times did not exceed one hour.
The DBP, SBP, and heart rate (HR) measurements were
recorded every 15 min over 24 h and while the patients
continued their normal daily activities. To be valid, an
ABPM recording had to have at least 48 adequate mea-
surements during 24 h and no more than 1 h of missing
data during the day or night.
Efficacy
The mean ABPM-derived SBP, DBP, PP (calculated from
individuals values of SBP and DBP), and HR values were
calculated for the whole 24-h period, the daytime period
(from 7 AM to 10 PM) and the nighttime period (from 10 PM
to 7 AM).
Trough (T) and peak (P) BP changes (M12–M0) were
calculated by considering the 2-h means of respectively
minimal drug efficacy (just before the next dose) or of
maximal drug effect. The ratios T/P were then ana-
lyzed.22–25 The T and P were evaluated only in patients
who responded to therapy, defined as subjects with a clinic
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mm Hg from M0 to M12.
In addition, the smoothness index (SI) was calculat-
ed.26,27 The SI is equal to H/SDH, where H is the
mean treatment-induced BP reduction for each hour dur-
ing the 24-h period and SDH is the standard deviation of
that mean. This parameter takes into account all BP mea-
surements over 24 h and integrates their possible fluctua-
tions. For a given BP reduction, a high SI indicates that the
treatment decreases the BP with low hourly variations
around the mean value. The SI was calculated on the
whole population.
The peak efficacy slope (PES, expressed as mm Hg/h)
was calculated by dividing the difference between the
set-up and the peak values for a given variable by the time
to reach peak efficacy (t). The PES was calculated only
for responder subjects as defined previously.
Safety
Safety assessment was based on the incidence of adverse
events among all the patients participating to the REA-
SON study.
Statistical Analyses
Data are expressed as mean  SD or percentages. The
comparability of the groups at baseline was assessed with
the Student t test for quantitative variables and the 2 test
for qualitative variables. The comparison of variation of
BP and heart rate between treatments was performed by
ANOVA or the Mann-Whitney U test when ANOVA was
not valid. The comparison of the smoothness index was
assessed with the Student t test and the comparison of PES
with Kruskal-Wallis test. P values  .05 were considered
to be significant.
Results
Efficacy
Among the 471 patients randomized in the REASON
trial,18,19 201 were analyzed in the ABPM study (107 in
the perindopril/indapamide group and 94 in the atenolol
group). The characteristics of the patients assigned to the
two arms did not differ significantly for the different pa-
rameters considered (Table 1) and did not differ from those
of the whole population.18,19 Dose adjustment was similar
in the two treatment groups (51/107 v 36/94). More than
70% of dose titration was performed at the 3-month visit.
At inclusion, SBP, DBP, PP, and HR measured by ABPM
were comparable in the two groups (Table 2).
After 1 year of perindopril/indapamide treatment, the
decreases of 24-h SBP, DBP, and PP were significant,
without significant reduction in the HR. In the atenolol
group, the decreases in 24-h SBP, DBP, and HR were
significant but the PP decrease was not significant. Anal-
yses performed on the daytime and nighttime monitoring
periods led to the same conclusions (Table 2, Figs. 1 to 3).For the whole 24-h period, the daytime period and the
nighttime period, the SBP reduction was significantly
greater for the perindopril/indapamide group than for the
atenolol group (for the whole 24 h, 13.8  11.9 v 9.2
 13.2 mm Hg; P  .01, respectively). For the three
periods, the PP reduction was also significantly greater for
the perindopril/indapamide group than for the atenolol
group (for the whole 24 h, 6.6  6.6 v 0.9  7.5 mm
Hg; P  .001). The SBP and PP reduction remain signif-
icantly different between perindopril/indapamide and
atenolol after adjustment on treatment adaptation. The
DBP declines were comparable for the two treatment arms
(7.2  7.3 for v 8.3  7.8 mm Hg; P  .30, respec-
tively). As expected, the HR was lowered significantly by
the -blocker, and not by perindopril/indapamide (11.0
 7.9 v 0.4  5.5 beats/min; P  .001).
The T/P ratios were calculated for all patients who
responded to treatment (as defined under Methods): 90
patients treated with perindopril/indapamide and 78 pa-
tients treated with atenolol. For SBP, the efficacy profile
was significantly better with perindopril/indapamide than
with atenolol, as the T/P ratio was higher (respectively
0.80 and 0.59). In contrast, the T/P ratio was similar
between the two groups for DBP (respectively, 0.67 and
0.69; Table 3).
The SI were calculated on the whole population of 201
patients (Table 3). For SBP, the SI was significantly higher
with perindopril/indapamide than with atenolol (respec-
tively, 1.45  1.24 v 0.98  1.42; P  .02). The DBP SI
of the two groups did not differ significantly (1.07  1.11
v 1.20  1.23; P .47, respectively).
The PES was calculated for all patients who responded
to treatment (n  168). The PES was lower with perin-
dopril/indapamide than with atenolol but the difference
was not statistically significant (respectively, 3.76 v
471 mm Hg/h; P  .31). The DBP PES was similar in
Table 1. Characteristics of the patients at inclusion
Characteristic
Perindopril/
indapamide
(n  107)
Atenolol
(n  94) P*
Age (y) 53.9  11.4 56.2  13.4 0.20
Range 25–77 26–82
Sex (male) 70% 67% 0.64
Body mass
index (kg/m2) 26.9  2.8 26.8  2.5 0.62
Office BP
(mm Hg)
SBP 162.1  13.1 160.9  15.3 0.54
DBP 97.8  7.5 97.6  8.1 0.88
PP 64.3  16.2 63.2  17.6 0.66
Values are mean  SD, unless indicated otherwise.
BP  blood pressure; DBP  diastolic blood pressure; PP  pulse
pressure; SBP  systolic blood pressure.
* Student t test or 2 test.the two groups (2.73 v 2.70 mm Hg/h; Table 3).
Table 2. Effects of perindopril/indapamide or atenolol on
Monitoring period
(Parameters,
mm Hg)
Perindopril/indapamid
enolol
 94)
P†M0 M12 M12 - M0 P*
24h
SBP 143.7  14.6 130.0  13.7  16.6 9.2  13.2 0.001 0.01
DBP 87.9  10.2 80.7  9.7 9.0 8.3  7.8 0.001 0.30
PP 55.8  11.7 49.2  9.6 13.1 0.9  7.5 0.26 0.001
Day (7 AM to 10 PM)
SBP 150.4  14.7 135.8  13.4  16.7 10.4  13.8 0.001 0.02
DBP 93.0  10.7 85.2  10.1 9.4 9.0  8.5 0.001 0.32
PP 57.4  12.3 50.6  10.0 13.3 1.5  7.9 0.08 0.001
Night (10 PM to 7 AM)
SBP 132.5  15.6 120.0  15.0  18.0 7.0  13.6 0.001 0.003
DBP 79.4  10.4 73.2  9.9 9.6 7.2  8.2 0.001 0.41
PP 53.1  11.2 46.8  10.0 13.1 0.2  7.8 0.78 0.001
Results are expressed as mean  SD.
* P intragroup Student t test.
† P intergroup, ANOVA, or Mann-Whitney U test when ANOVA was not v
M0, M12, months 0 (inclusion) and 12 (end) of the study; other abbrev
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249AJH–March 2004–VOL. 17, NO. 3 ABPM OF PERINDOPRIL/INDAPAMIDE COMBINATIONperindopril/indapamide group. The incidence of hypoka-
lemia (3.4 mmol/L) was 1.3% with atenolol and 3.0%
with perindopril/indapamide. No relevant changes over
time were detected for the other laboratory parameters.
Discussion
In the present study, the antihypertensive effects of the
perindopril/indapamide first-line combination were com-
pared to those of the -blocking agent atenolol. After 12
months of perindopril/indapamide treatment, SBP and PP
were decreased significantly more during the day, the
night, and over 24 h as compared to atenolol. No signifi-
cant difference was observed for DBP between the two
treatments regardless of the period analyzed (entire 24 h,
day or night). As would be expected with a -blocker, the
HR was lowered significantly by atenolol but not by the
FIG. 3. Effects () of perindopril/indapamide and atenolol on 24-h
pulse pressure (PP).
Table 3. Calculated parameters: trough/peak
(T/P) ratio, smoothness index (SI) and peak efficacy
slope (PES) after 12-month treatment
Perindopril/
indapamide Atenolol P*
T/P ratio (%) (n  90)† (n  78)†
SBP 80% 59% NA
DBP 67% 69% NA
SI (n  107) (n  94)
SBP 1.45  1.24 0.98  1.42 0.02
DBP 1.07  1.11 1.20  1.23 0.47
PES (mm Hg/h) (n  90)† (n  78)†
SBP 3.76  4.44 4.71  5.23 0.31
DBP 2.73  2.96 2.70  3.18 0.78
Results are expressed as mean  SD, unless otherwise indicated.
* Student t test for comparison of SI; Kruskal-Wallis test for
comparison of PES.
† T/P ratio and PES were calculated for responding patients.
NA  not applicable; other abbreviations as in Table 1.perindopril/indapamide combination. Finally, PP was sig-
nificantly reduced by the perindopril/indapamide combi-
nation during the whole 24 h, whereas it was unaffected by
atenolol.
These results from ABPM investigation are consistent
with the results from the main REASON study, in which
the effects of atenolol and perindopril/indapamide on ar-
terial pressure were assessed by mercury sphygmomanom-
eter measurements.18 Indeed, in the latter study, a greater
decrease in brachial artery SBP and PP was achieved with
perindopril/indapamide than with atenolol. A similar find-
ing was also observed using noninvasive central (thoracic
aorta, carotid artery) BP measurements.18,19 Thus, the
selective reduction in SBP and PP under the perindopril/
indapamide combination was demonstrated using three
independent methods of BP measurements (brachial artery
using conventional mercury sphygmomanometer, central
arteries with noninvasive measurements, and ABPM). Re-
garding PP, the difference between the two drug regimens
could be attributed to specific and independent effect of
each regimen on arterial stiffness and wave reflections.
More distant reflecting sites or change in the reflective
properties of these sites induced by the perindopril/ inda-
pamide combination but not by atenolol might be an
explanation for differential patterns of wave reflections
with a more substantial reduction of SBP and PP on
perindopril/indapamide than on atenolol.18,19 The combi-
nation of the two drugs perindopril and indapamide and
not the ACE inhibitor treatment alone was responsible for
the selective SBP and PP reduction.27,28
The more marked effect of perindopril/indapamide on
SBP and PP as compared to the reference treatment merits
consideration because SBP and PP in patients 50 years
of age are the most relevant mechanical factors predicting
cardiovascular risk.8,10,29–32 The predictive value of PP is
known to be superior for ABPM than for clinic PP.8 The
PP measurements are poorly modified by placebo, what-
ever the device.33 In the SystEur trial, Staessen et al34 have
shown that an increased nocturnal PP with ABPM is a
very sensitive predictor of cardiovascular complications in
treated patients. It is noteworthy that the perindopril/inda-
pamide combination in our study was shown to normalize
PP even during the nocturnal period.
There is considerable evidence that high BP should be
reduced by antihypertensive drug treatment in a smooth
and consistent fashion.3–11 The T/P ratio has been pro-
posed as an index to assess the ability of a drug to induce
smooth or irregular BP decreases.21–23 In our study, the
efficacy at trough SBP was significantly better with per-
indopril/indapamide than with atenolol. The T/P ratio has
some limitations, however, particularly with regard to the
nongaussian distribution of the values and its poor repro-
ducibility. The latter finding can essentially be explained
by the use of only two short segments of the whole
recording to calculate the index. Thus, it is possible that
the BP measurement retained are more representative of
BP fluctuations than of the effect of treatment.
250 AJH–March 2004–VOL. 17, NO. 3ABPM OF PERINDOPRIL/INDAPAMIDE COMBINATIONAs an alternative to the T/P ratio, the SI has been
proposed as a more reproducible measure of the evenness
of BP reduction. In addition, the SI has been shown to
predict better the regression in left ventricular hypertrophy
in treated hypertensive patients than the T/P ratio.25 In the
REASON study it has been shown that cardiac mass was
significantly more reduced by perindopril/indapamide than
by atenolol.35 More recently, Rizzoni et al26 showed the
superiority of SI over the T/P ratio for predicting changes
of carotid wall thickness during antihypertensive drug
therapy. Therefore, the finding that the SBP SI of the
perindopril/indapamide group was significantly higher
than that of the atenolol group suggests that BP reduction
in the former group occurred with fewer fluctuations in
BP.
In conclusion, in this 1-year clinical study, the perin-
dopril/indapamide first-line combination decreased SBP
and PP more effectively than atenolol. Moreover, with the
perindopril/indapamide combination the BP control effect
was smooth and consistent throughout the 24-h dosing
interval, and variability in BP reduction was less than that
induced by atenolol.
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